The introduction of ABL1 tyrosine kinase inhibitors (TKIs) has improved survival outcomes for patients with chronic phase chronic myeloid leukemia (CML-CP) markedly [1]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.